恩格列净与肾结石风险降低:SGLT2抑制的潜在新作用?
汇总20项I-IV期随机试验中15081例2型糖尿病患者数据,比较恩格列净(n=10177)与安慰剂(n=4904)的尿路结石事件。恩格列净组年发生率1.01 vs 0.63事件/100患者年,IRR 0.64(95%CI 0.48-0.86),敏感性分析IRR 0.62(95%CI 0.45-0.85)。作者认为恩格列净与尿路结石事件风险约降低40%相关,机制可能涉及尿液成石性改变,需专门随机前瞻性临床试验确认。
要点
- 恩格列净组尿路结石年发生率1.01 vs 安慰剂组0.63事件/100患者年,IRR 0.64(95%CI 0.48-0.86)。
- 敏感性分析采用更窄定义,结果相似:IRR 0.62(95%CI 0.45-0.85)。
- 作者认为机制未知,可能涉及尿液成石性改变,需专门随机前瞻性临床试验确认。
核心结论
- 与安慰剂相比,恩格列净治疗与2型糖尿病患者尿路结石事件风险约降低40%相关。
- 作者认为潜在机制未知,可能涉及尿液成石性改变。
- 作者指出需专门的随机前瞻性临床试验在有和无2型糖尿病的患者中确认这些初步观察。
研究设计与样本
- 汇总20项I-IV期随机临床试验数据,共15081例2型糖尿病患者,随机分配至恩格列净(n=10177)或安慰剂(n=4904),包括大型心血管结局试验EMPA-REG OUTCOME。
- 采用预设的MedDRA术语集收集新发尿路结石事件,并采用更窄定义进行敏感性分析。
- 按研究分层计算发生率比(IRR)及95%CI。
主要发现
- 研究中位药物暴露时间:安慰剂组543天,恩格列净组549天。
- 随访期间183例患者发生新发尿路结石(安慰剂组79例,恩格列净组104例)。
- 两组年发生率分别为1.01 vs 0.63事件/100患者年,IRR为0.64(95%CI 0.48-0.86),有利于恩格列净。
- 敏感性分析结果相似:IRR为0.62(95%CI 0.45-0.85)。
关键数值与推荐
- 恩格列净组尿路结石年发生率1.01事件/100患者年 vs 安慰剂组0.63事件/100患者年。
- 主要分析IRR 0.64(95%CI 0.48-0.86),敏感性分析IRR 0.62(95%CI 0.45-0.85)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者指出潜在机制未知。
- 作者指出需专门的随机前瞻性临床试验在有和无2型糖尿病的患者中确认这些初步观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diabetes mellitus is a risk factor for nephrolithiasis. A recent observational study found that in patients with type 2 diabetes (T2D), SGLT2 inhibitor use was associated with a 49% lower risk of nephrolithiasis compared with GLP-1 receptor agonists. OBJECTIVE: We examined the association between nephrolithiasis and the SGLT2 inhibitor empagliflozin, using existing data from randomized clinical trials. METHODS: We pooled data from 15 081 T2D patients randomized to empagliflozin (n = 10 177) or placebo (n = 4904) from 20 phase I-IV trials, including the large cardiovascular outcome trial, EMPA-REG OUTCOME. Incident urinary tract stone events were captured using a predefined collection of MedRA terms. A sensitivity analysis using a narrower definition was also performed. Incidence rate ratios (IRR) and 95% CIs were calculated using the relative risk estimate, stratified by study. RESULTS: The median exposures to study drug were 543 days (placebo) and 549 days (empagliflozin); 183 patients experienced an incident urolithiasis during follow-up (placebo, 79; empagliflozin, 104), yielding annual incidence rates of 1.01 vs 0.63 events/100 patient-years in the 2 respective groups. The IRR was 0.64 (95% CI, 0.48-0.86), in favor of empagliflozin. In the sensitivity analysis, the results were similar (IRR, 0.62 [95% CI, 0.45-0.85]). CONCLUSION: Compared with placebo, empagliflozin therapy was associated with an approximate 40% reduced risk of urinary tract stone events in T2D patients. The underlying mechanisms are unknown but may involve altered lithogenic profile of the urine. Dedicated randomized prospective clinical trials are warranted to confirm these initial observations in patients with and without T2D.
引用
- Balasubramanian P, Wanner C, Ferreira JP, et al. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? J Clin Endocrinol Metab. 2022. PMID: 35290464. doi:10.1210/clinem/dgac154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。